Semaglutide FAQ: Dosing, Storage, Reconstitution, and More

By NorthPeptide Research Team  |  May 5, 2026

What Is Semaglutide?

Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone secreted by intestinal L-cells in response to food intake. It was developed by Novo Nordisk and has been approved under three brand names: Ozempic (once-weekly subcutaneous injection for type 2 diabetes), Wegovy (once-weekly subcutaneous injection for chronic weight management), and Rybelsus (once-daily oral tablet for type 2 diabetes).

Semaglutide differs from native GLP-1 — which has a plasma half-life of approximately 2 minutes — through three structural modifications: an Ala→Aib substitution at position 8 that confers DPP-IV resistance, a C18 fatty diacid chain attached via a linker at position 26 that enables albumin binding for extended circulation, and a Lys→Arg substitution at position 34. These changes extend the half-life to approximately 7 days, enabling once-weekly dosing.

How Does the GLP-1 Mechanism Work?

GLP-1 receptor (GLP-1R) agonism produces effects across multiple organ systems:

• Pancreas: Glucose-dependent stimulation of insulin secretion from beta cells and suppression of glucagon from alpha cells. The glucose-dependence of these effects is critical — semaglutide only enhances insulin release when blood glucose is elevated, dramatically reducing hypoglycemia risk compared to insulin or sulfonylureas.
• Brain: GLP-1R activation in the arcuate nucleus of the hypothalamus stimulates anorexigenic POMC neurons and inhibits orexigenic NPY/AgRP neurons, reducing hunger and increasing satiety. Neuroimaging studies demonstrate reduced food reward center activation.
• Stomach: Slowed gastric emptying blunts postprandial glucose excursions and prolongs satiety after meals.
• Heart: GLP-1R on cardiomyocytes mediate cardioprotective effects. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in non-diabetic adults with obesity and established cardiovascular disease.

Q: What is the difference between semaglutide, Ozempic, and Wegovy?

They are the same molecule — semaglutide — administered in different dose ranges and approved for different indications:

• Ozempic: 0.25 mg, 0.5 mg, 1 mg, or 2 mg once weekly subcutaneously, approved for type 2 diabetes management and cardiovascular risk reduction.
• Wegovy: 2.4 mg once weekly subcutaneously, approved for chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidity).
• Rybelsus: 3 mg, 7 mg, or 14 mg once daily orally, approved for type 2 diabetes. Uses the SNAC absorption enhancer to overcome gastrointestinal degradation.

In research, the compound is identical regardless of brand name. The distinction matters primarily for regulatory and dosing purposes.

Q: How do you reconstitute semaglutide?

Research-grade semaglutide is supplied as a lyophilized (freeze-dried) powder. Standard reconstitution protocol:

1. Allow the vial to reach room temperature before opening (reduces thermal shock).
2. Draw the required volume of bacteriostatic water (0.9% benzyl alcohol) into a clean syringe.
3. Inject the bacteriostatic water slowly down the inner wall of the vial — do not inject directly onto the peptide cake, and do not shake.
4. Gently swirl or roll the vial until the powder is fully dissolved. The solution should be clear and colorless.
5. Label the vial with the reconstitution date.

Example: To reconstitute a 2 mg vial to 1 mg/mL, add 2 mL of bacteriostatic water. Each 0.25 mL drawn = 0.25 mg.

Q: What dosing schedule is used in research?

Clinical trial protocols (STEP and SUSTAIN programs) used the following subcutaneous injection schedules:

Weeks	Dose (weight management)	Purpose
1–4	0.25 mg/week	Initiation / GI tolerance
5–8	0.5 mg/week	Escalation
9–12	1.0 mg/week	Escalation
13–16	1.7 mg/week	Escalation
17+	2.4 mg/week	Maintenance (Wegovy dose)

Slow titration is the primary strategy for managing GI side effects. In clinical trials, patients who experienced intolerable GI effects remained at the previous dose level for an additional 4 weeks before re-attempting escalation.

Q: Why is titration important?

Semaglutide’s GI side effects — nausea, vomiting, diarrhea — are dose-dependent and most pronounced during dose escalation. The delayed gastric emptying that semaglutide induces causes the GI tract to adjust over weeks to months. Starting at a low dose and escalating gradually allows the enteric nervous system and GI motility to adapt, dramatically reducing the severity of side effects. In the STEP 1 trial, GI events led to discontinuation in only 4.5% of semaglutide-treated subjects — largely attributable to the structured 16-week titration protocol.

Q: How long does a reconstituted vial last?

Reconstituted semaglutide stored at 2–8°C (standard refrigerator temperature) maintains stability for approximately 28 days. The benzyl alcohol in bacteriostatic water acts as a preservative and allows multi-dose use over this period. Key storage rules:

• Never freeze reconstituted semaglutide — freezing can cause aggregation and loss of potency.
• Protect from direct light.
• Discard any solution that appears cloudy, discolored, or contains particles.
• Use within 28 days of reconstitution regardless of remaining volume.

Q: What are the storage requirements for unreconstituted semaglutide?

• Long-term: -20°C (standard laboratory freezer). Stability maintained for 12–24 months under these conditions.
• Short-term: 2–8°C (refrigerator) for up to 30 days prior to reconstitution.
• Avoid temperature cycling (repeated freeze-thaw). If received at room temperature, refrigerate promptly.
• Keep desiccant pack in vial container during storage.

Q: What side effects has semaglutide produced in clinical trials?

The STEP and SUSTAIN programs generated comprehensive safety data from thousands of participants:

• Nausea: 44% of subjects at 2.4 mg. Most pronounced during dose escalation; attenuates substantially with time. Eating smaller, lower-fat meals and avoiding supine position immediately after eating reduces severity.
• Diarrhea: ~30%. Usually transient and self-limiting during titration.
• Vomiting: ~24%. Most often accompanies nausea during the first 4–8 weeks.
• Constipation: ~24%. Can persist longer than nausea/vomiting in some subjects.
• Pancreatitis: Rare, but elevated relative to placebo. Subjects with prior pancreatitis history were excluded from STEP trials.
• Gallbladder events: Increased rate of cholelithiasis consistent with rapid weight loss (a class effect across weight management agents).
• Muscle mass: Approximately 25–40% of total weight lost is lean mass. This has driven research interest in combining semaglutide with resistance training protocols and anabolic support.
• Thyroid C-cell tumors: Observed in rodents; not replicated in human trials or post-marketing surveillance. Considered a rodent-specific finding due to different GLP-1R expression patterns on thyroid C-cells in rodents versus humans. Class-wide boxed warning remains.

Q: Can semaglutide be stacked with other peptides in research?

Several combination approaches are being actively investigated:

• CagriSema (semaglutide + cagrilintide): Novo Nordisk’s fixed-dose combination of semaglutide with the amylin analog cagrilintide. Phase 3 REDEFINE trials are evaluating this combination, with preliminary Phase 2 data showing weight loss of approximately 15–17% — somewhat lower than anticipated given the dual mechanism, though Phase 3 designs aim to optimize the combination.
• BPC-157: Some research protocols investigate GLP-1 agonists alongside gut-protective peptides like BPC-157 to study whether gastroprotective effects may attenuate GI side effects. No peer-reviewed combination trials have been published.
• Sermorelin / CJC-1295: Combination with GHRH analogs has been discussed in the context of preserving lean mass during GLP-1-driven weight loss. Growth hormone secretagogues may help offset the muscle loss associated with caloric deficit induced by GLP-1 agonists. This remains an area of ongoing investigation.

Researchers should note that adding compounds to GLP-1 agonist protocols introduces additional pharmacological variables and requires careful study design to isolate effects.

Q: What is the difference between oral and injectable semaglutide?

The oral formulation (Rybelsus) uses the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer, which locally elevates gastric pH and promotes transcellular absorption across the gastric mucosa. Bioavailability is approximately 0.4–1% — the vast majority of the oral dose is not absorbed. Despite low bioavailability, therapeutic plasma concentrations are achievable at doses of 7–14 mg.

Key differences from subcutaneous administration:

• Must be taken fasting with ≤4 oz of water, 30 minutes before food or other medications.
• Plasma concentration curve is less smooth than subcutaneous (shorter absorption window).
• Slightly lower glycemic efficacy compared to subcutaneous at equivalent doses.
• No injection required — relevant for subjects with needle aversion.
• Higher doses in development: oral semaglutide 25 mg and 50 mg are in late-stage clinical trials for weight management (OASIS and ACHIEVE programs).

Q: How important is purity in semaglutide research?

For any research compound, purity determines the reliability and reproducibility of experimental results. For semaglutide specifically:

• HPLC purity ≥98%: The industry standard for research-grade peptides. Lower purity means more impurities — related peptide fragments, oxidation products, or synthesis byproducts — that can confound results.
• Mass spectrometry verification: Confirms the correct molecular weight and sequence, ruling out gross substitution or degradation.
• Certificate of Analysis (CoA): Should be batch-specific, third-party tested, and available for review before purchase. Generic or undated CoAs are a red flag.
• Endotoxin testing: LAL (Limulus Amebocyte Lysate) testing for bacterial endotoxin is essential for any injectable research application. Endotoxin contamination can produce inflammatory responses that confound pharmacological data.

Q: How do I verify the quality of research-grade semaglutide?

Quality verification for research peptides should include:

1. Third-party CoA: Verify purity via HPLC (≥98%) and identity via mass spectrometry, from a laboratory independent of the supplier.
2. Batch traceability: Each vial should have a batch/lot number traceable to a specific CoA.
3. Supplier reputation: Look for GMP-manufactured peptides, transparent sourcing, and published test results — not just marketing claims.
4. Physical inspection: Lyophilized peptide should be a white to off-white powder or cake. Brown discoloration, clumping, or unusual odor are signs of degradation.

Q: What are the shipping and handling considerations for semaglutide?

Semaglutide is stable at room temperature for short periods during transit (typically up to 14–30 days), which is why lyophilized forms do not require cold-chain shipping in most cases. However:

• Avoid leaving packages in hot environments (e.g., a car in summer) — sustained high temperatures can accelerate degradation.
• Refrigerate promptly upon receipt if not using immediately.
• If a shipment appears to have been exposed to heat or moisture, contact the supplier and request a new batch before use.
• International shipments may face customs review; peptides should be accompanied by research-use documentation.

Q: What does the clinical trial data show about long-term weight maintenance?

The STEP 4 withdrawal trial is the most important study on this question. After 20 weeks on semaglutide 2.4 mg, participants were randomized to either continue semaglutide or switch to placebo. The placebo group regained approximately two-thirds of their lost weight over the following 48 weeks, while the semaglutide group maintained their loss. STEP 5 (2-year data) confirmed that continued treatment sustains weight reduction of approximately 15.2% from baseline at 104 weeks.

This pattern establishes semaglutide as a chronic-use treatment for weight management rather than a short-course intervention — paralleling how chronic conditions like hypertension or hypothyroidism require ongoing pharmacological management.

Q: What is the SELECT trial and why does it matter?

The SELECT trial (2023) enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, but without diabetes. Semaglutide 2.4 mg weekly reduced MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% versus placebo over a mean follow-up of ~3.3 years. This was the first demonstration that a weight management medication reduces cardiovascular events independently of diabetes treatment, establishing semaglutide as a cardiometabolic drug rather than simply a metabolic one (PMID 37608589).

Q: How does semaglutide compare to tirzepatide and retatrutide?

The incretin agonist field has rapidly evolved beyond GLP-1 mono-agonism:

Compound	Targets	Approx. Weight Loss	Status (2026)
Semaglutide 2.4 mg	GLP-1R	~15%	FDA-approved (Wegovy)
Tirzepatide 15 mg	GLP-1R + GIPR	~21%	FDA-approved (Zepbound)
Retatrutide 12 mg	GLP-1R + GIPR + GCGR	~24% (Phase 2)	Phase 3 trials ongoing

For researchers studying the next generation of incretin-based compounds, Retatrutide is available in our research catalog. Its triple-agonist mechanism — adding glucagon receptor activity to GLP-1 and GIP agonism — is the subject of ongoing Phase 3 trials and represents the current frontier of metabolic peptide research.

PubMed References

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. PMID 33567185
2. Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021;397:971–984. PMID 33667417
3. Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325:1414–1425. PMID 33755728
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. PMID 37608589
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834–1844. PMID 27633186
6. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165. PMID 16517403